{"schema_version":"1.0","type":"article","title":"默沙東口服藥殺進「降膽固醇針」市場，誰會被搶走？","url":"https://drugnews.com.tw/articles/2026-08-26-merck-lipfendra-oral-pcsk9.html","markdown_url":"https://drugnews.com.tw/articles/2026-08-26-merck-lipfendra-oral-pcsk9.md","lang":"zh-Hant","date":"2026-08-26","publish_at":"2026-08-26T08:00:00+08:00","updated_at":"2026-08-26","category":"商業分析系列","topic":"商業分析系列","tags":["默沙東","Lipfendra","enlicitide","PCSK9","膽固醇","心血管","諾華","Leqvio","台灣健保"],"summary":"FDA 核准首款每日口服 PCSK9 抑制劑 Lipfendra，兩項第三期試驗在第 24 週降低 LDL-C 56% 與 59%。但口服不等於針劑退場：心血管硬終點、每日空腹依從性、保險准入與台灣核准，才會決定市場如何重切。","key_points":[],"facts":[],"sections":["01｜第一顆口服 PCSK9，突破在哪裡？","02｜口服對上半年一針，誰才真的方便？","03｜LDL-C 降得漂亮，還不等於心肌梗塞真的變少","04｜市場預期為何分化？兩家公司賣的不是同一種體驗","05｜台灣真正要看的：方便之外，還有核准與健保","結語｜第一顆口服 PCSK9 打開大門，沒有宣判針劑死刑","主要參考資料"],"references":[{"title":"[FDA","source":"2026 Novel Drug Approvals]","date":"","url":"https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026"},{"title":"[FDA","source":"Lipfendra 核准函（NDA 220848）]","date":"","url":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220848Orig1s000ltr.pdf"},{"title":"[FDA","source":"First Oral PCSK9 Inhibitor]","date":"","url":"https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-pcsk9-inhibitor-lower-ldl-cholesterol-adults-high-cholesterol"},{"title":"[Lipfendra","source":"FDA-approved prescribing information]","date":"","url":"https://www.merck.com/product/usa/pi_circulars/l/lipfendra/lipfendra_pi.pdf"},{"title":"[默沙東","source":"Lipfendra FDA 核准公告]","date":"","url":"https://www.merck.com/news/mercks-lipfendra-enlicitide-is-the-first-and-only-once-daily-oral-pcsk9-inhibitor-approved-by-the-u-s-fda-to-reduce-ldl-c-in-adults-with-hypercholesterolemia/"},{"title":"[默沙東","source":"2026 年第二季財報（SEC 8-K Exhibit 99.1）]","date":"","url":"https://www.sec.gov/Archives/edgar/data/310158/000110465926090045/tm2621496d1_ex99-1.htm"},{"title":"[CORALreef Lipids","source":"NCT05952856]","date":"","url":"https://clinicaltrials.gov/study/NCT05952856"},{"title":"[CORALreef HeFH","source":"NCT05952869]","date":"","url":"https://clinicaltrials.gov/study/NCT05952869"},{"title":"[CORALreef Outcomes","source":"NCT06008756]","date":"","url":"https://clinicaltrials.gov/study/NCT06008756"},{"title":"[Novartis","source":"2026 年第二季財報]","date":"","url":"https://www.novartis.com/news/media-releases/novartis-delivered-sales-growth-q2-and-further-advanced-pipeline-full-year-guidance-reaffirmed"},{"title":"[ACC／AHA","source":"2026 血脂異常指引]","date":"","url":"https://professional.heart.org/en/science-news/2026-guideline-on-the-management-of-dyslipidemia"},{"title":"[衛生福利部中央健康保險署","source":"PCSK9 注射型降脂藥給付放寬]","date":"","url":"https://www.nhi.gov.tw/ch/cp-18857-f1abb-3255-1.html"},{"title":"> 免責聲明：本文為生技醫藥產業與公開資料整理，不構成投資、醫療或用藥建議。Lipfendra 的 LDL-C 降幅來自各自試驗內相較安慰劑的校正結果；不同產品未在同一場頭對頭試驗中直接比較。Lipfendra 的專屬大型心血管結局試驗仍在進行。","source":"","date":"","url":""}],"images":[{"alt":"圖 1｜默沙東把原本由注射主導的 PCSK9 靶點做成每日口服藥，但口服不等於針劑退場","url":"https://drugnews.com.tw/assets/articles/merck-lipfendra-oral-pcsk9/figure-01.png"},{"alt":"圖 2｜Lipfendra 阻止 PCSK9 與 LDL 受體結合，讓受體留在肝細胞表面清除更多 LDL-C","url":"https://drugnews.com.tw/assets/articles/merck-lipfendra-oral-pcsk9/figure-02.png"},{"alt":"圖 3｜每日口服、院所低頻注射與已有硬終點證據的 PCSK9 單抗，是三套不同的依從性與證據邏輯","url":"https://drugnews.com.tw/assets/articles/merck-lipfendra-oral-pcsk9/figure-03.png"},{"alt":"圖 4｜口服 PCSK9 從 LDL-C 降幅走到真實市場，仍要通過心血管硬終點、醫師與支付准入、台灣核准與健保四道門","url":"https://drugnews.com.tw/assets/articles/merck-lipfendra-oral-pcsk9/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/merck-lipfendra-oral-pcsk9/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-08-26）。默沙東口服藥殺進「降膽固醇針」市場，誰會被搶走？。https://drugnews.com.tw/articles/2026-08-26-merck-lipfendra-oral-pcsk9.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-08-26-merck-lipfendra-oral-pcsk9-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}